Skip to content
DataLookout
Menu

NCT05931328

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2023); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Overall Response Rate (ORR)
Timeframe: Baseline up to 2 years.
Adverse event rate
Timeframe: Baseline up to 3 years.

Secondary (3)

2-year Progression-free Survival (PFS) rate
2-year Overall Survival(OS)rate
Duration of Response(DOR)

Arms and interventions

thiotepa+pomalidomideExperimental

thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.

Drugs: thiotepa combined with pomalidomide

Sites

1 site in 1 country

  • Jiangsu Province People's Hospital.Nanjing, Jiangsu, China